JAZZ ▲ +0.0% - Jazz Pharmaceuticals plc $JAZZ JAZZ - Ziihera® (zanidatamab-hrii) plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Versus Trastuzumab plus Chemotherapy in First-Line HER2+ Advanced GEA Jazz Pharmaceuticals announced that its drug Ziihera (zanidatamab-hrii) combined with chemotherapy achieved a statistically significant overall survival benefit compared to trastuzumab plus chemotherapy in first-line treatment of HER2+ advanced gastroesophageal cancer. This positive clinical trial result for a potentially important cancer indication would typically be expected to drive investor interest, though the stock showed no net movement today, suggesting the market may have already priced in expectations around this trial outcome. 31-AUG-2026 06:00 AM ET